We present new risk nomograms by PROMISE along with a simple table to prognosticate 3-year, 5-year, and 7-year overall survival in prostate cancer. PROMISE and PPP3 assessments are freely available online for global implementation.
The Lancet Oncology published a clinical update in Oncology on 09 Mar 2026.
The item focuses on New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.
Review the original article for the full source wording and details.